Quick Dispatch:
Your surmount-1 trial tirzepatide non-diabetic weight loss SURMOUNT 1 // Three-Year Obesty & Diabetes Prevention Outcomes orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your surmount-1 trial tirzepatide non-diabetic weight loss SURMOUNT 1 // Three-Year Obesty & Diabetes Prevention Outcomes ships.
Need Help?
Questions about surmount-1 trial tirzepatide non-diabetic weight loss SURMOUNT 1 // Three-Year Obesty & Diabetes Prevention Outcomes, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for surmount-1 trial tirzepatide non-diabetic weight loss SURMOUNT 1 // Three-Year Obesty & Diabetes Prevention Outcomes in your area.
SURMOUNT-1 (NEJM 2022) tested tirzepatide — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with obesity and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants
27.49
Tirzepatide cuts diabetes risk by 94% in SURMOUNT-1 trial
21.16
Tirzepatide Demonstrates 94% Diabetes Reduction, 22% Weight Loss in SURMOUNT -1 Study
22.80
Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial
21.93
SURMOUNT 1 // Three-Year Obesty & Diabetes Prevention Outcomes
25.08
For the first time, tirzepatide and semaglutide were put in the same trial. SURMOUNT-5. Phase 3b RCT. 751 adults with obesity, no diabetes. 72 weeks. Both drugs at maximum tolerated dose. The
21.92
Weight reduction over time in tirzepatide‐treated participants by early weight loss response: Post hoc analysis in SURMOUNT‐1 - Ard - 2025 - Diabetes, Obesity and Metabolism
28.59
